However, VEGF-targeted therapy is restricted by its transient responses in the clinic due to drug resistance and it has been reported that the agents were not effective for all tumor types, indicating that blocking VEGF activation alone may not be sufficient to completely halt tumor angiogenesis, since angiopoietin and other factors are also involved. This evidence concerns the gene VEGFA and neoplasm.